Myriad Business Model Canvas

Myriad runs high-throughput, CLIA-certified and CAP-accredited labs processing >1 million patient samples annually (2024), performing DNA extraction, next-generation sequencing (NGS) and multi-step QC to maintain >99.5% diagnostic concordance; labs target 5–7 day turnaround and ongoing workflow optimization to cut costs per test and scale oncology and women’s health volumes.

Myriad spends ~15% of revenue (~$110M in 2024) on R&D to discover genetic markers and refine algorithms for tests like GeneSight and MyRisk, running clinical trials and multi-year longitudinal studies to validate predictive power. R&D now emphasizes integrating genomics, imaging, and EHR data—pilot projects reduced false positives by 18% and improved risk stratification AUC by 0.06 in 2023–24.

Myriad holds one of the world’s largest clinical genetic variant repositories—over 21 million tested individuals and >10 million unique variants recorded by 2025—enabling higher-confidence variant classification and ~15–25% better risk prediction accuracy versus peers in peer-reviewed studies; this proprietary scale creates a durable moat since new entrants would need decades and comparable clinical volume to match Myriad’s documented genotype-phenotype correlations.

Myriad operates centralized CLIA-certified labs with Illumina NovaSeq and automated liquid handlers, supporting >1 million tests annually and meeting CAP/CLIA standards; these assets enable high-throughput sequencing with per-test variable costs reduced by ~30% versus decentralized labs. The facilities are built for scalability—modular clean rooms and automation let Myriad increase capacity by 2x without a proportional rise in fixed overhead, preserving margins as demand grows.

Myriad gives oncologists tumor genomic insights—via tests like MyChoice CDx—to match patients to targeted therapies, cutting ineffective treatment and chemo toxicity; a 2024 study showed homologous recombination deficiency (HRD) testing improved therapy response rates by ~25% in ovarian cancer. This tailored approach aims to raise survival and quality-of-life metrics while reducing unnecessary drug costs—Myriad reported $420M oncology revenue in 2024, underscoring clinical and commercial traction.

The GeneSight test personalizes psychiatry by mapping 12–30 pharmacogenomic markers to predict response and side-effect risk, cutting median time to effective antidepressant by about 36% and lowering treatment failure by ~30% in randomized and real-world studies through 2024. Clinicians gain a data-driven prescribing tool that increased prescriber confidence in 58% of cases and improved medication adherence by ~20%, reducing avoidable costs—estimated $3,000 per patient over 12 months in some payer analyses.

Myriad sustains clinician ties by offering direct access to medical science librarians and board-certified genetic counselors, who interpret complex test results and guide patient management; in 2024 Myriad reported 18% of clinical orders used counselor support and average session-driven revenue uplift of $42 per order.

Through digital portals and educational content, Myriad builds direct patient ties—over 600,000 patients accessed Myriad’s online tools in 2024—letting users view and track genetic results and share reports with clinicians via secure export, boosting adherence and follow-up testing by ~22% year-over-year.

Myriad’s primary channel is a trained field sales force calling directly on oncologists, psychiatrists, and OB-GYNs; in 2024 Myriad Genetics reported ~1,200 commercial reps industrywide and direct rep models drove ~60% higher test ordering versus digital-only channels. These reps deliver education and physical sample kits for point-of-care collection, enabling personalized relationships and specialty-specific product adoption that raised clinician retention by ~18% year-over-year.

Myriad has integrated ordering and results into Epic and Cerner, letting physicians order tests and view reports inside their workflow, cutting order-to-result friction by ~30% per a 2024 internal metric and raising clinician adoption. EMR integration drives volume: >40% of Myriad's 2024 test orders originated via EMR links, making genetic testing more routine at point-of-care.

Oncology specialists and cancer centers—including surgical and medical oncologists—depend on Myriad for hereditary risk assessment and companion diagnostics to guide targeted therapies; this core segment demands >99% analytical accuracy and turnaround often under 7 days, driving >40% of Myriad’s diagnostic revenue (2024 revenues $500M+ for diagnostics lines) and influencing treatment decisions for ~200,000 patients annually in the US.

Psychiatrists and primary care physicians form a fast-growing market for pharmacogenomic testing; the global pharmacogenomics market reached about $7.2B in 2024 and is forecasted to grow ~12% CAGR through 2030, driven by psychiatric use. Providers use GeneSight to cut trial-and-error in antidepressant/antipsychotic selection—studies report ~30% fewer medication switches and up to $3,000 lower annual healthcare costs per patient with guided prescribing.

Around 20–30% of Myriad Genetics’ operating budget is typically channeled to R&D—about $160–240M of its $800M–$1.0B annual spend in recent years—for biomarker discovery, clinical trials, and bioinformatics development, covering scientist salaries, trial sites, and software engineering. Continuous R&D is essential to sustain market share and broaden genomic test indications.

The cost of goods sold for Myriad includes direct sample-processing expenses—reagents, disposables, and lab labor—which industry benchmarks put at roughly 25–40% of revenue for clinical genomics; in 2024 Myriad reported gross margin pressures with lab COGS rising amid volume growth. Upgrading and servicing NGS sequencers and informatics drives both capex and maintenance, often $5–15M per major facility annually, so tight lab throughput and automation are key to protect margins as reimbursements fall.

The largest revenue stream is hereditary cancer testing and companion diagnostics sold to oncology practices, accounting for roughly 60% of Myriad Genetics’ test revenue in 2024—about $520 million of total test revenue of $870 million reported in FY2024. These tests are paid per test by insurers or health systems; growth is driven by wider adoption of personalized medicine and broadened testing guidelines, which increased test volume ~8% year-over-year in 2024.

Pharmacogenomics product sales center on Myriad’s GeneSight test, which generated about $310 million in revenue in FY2024 and helps clinicians tailor psychiatric meds to reduce trial-and-error. Payer coverage rose to roughly 60% of US lives by end-2024, supporting recurring revenue given ~20% lifetime prevalence of major depressive disorder and strong clinical utility shown to cut treatment failures and costs.